17,033 Shares in Pfizer Inc. $PFE Acquired by Revisor Wealth Management LLC

Key Points

• Revisor Wealth Management LLC has acquired 17,033 shares of Pfizer Inc. for approximately $439,000 in the second quarter, contributing to the 68.36% of the stock owned by institutional investors.
• Several analysts have recently adjusted their price targets for Pfizer, with Citigroup setting it at $26.00 and Bank of America raising it to $28.00, while Wall Street Zen upgraded Pfizer from a "hold" to a "buy" rating.
• Pfizer reported an EPS of $0.78 for the last quarter, exceeding consensus estimates and achieving a revenue of $14.65 billion, marking a 10.3% increase year-over-year.

Revisor Wealth Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,033 shares of the biopharmaceutical company's stock, valued at approximately $439,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer during the 4th quarter valued at $30,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer during the 1st quarter valued at $35,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.12 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a fifty day moving average of $24.60 and a 200-day moving average of $24.18. The company has a market capitalization of $137.14 billion, a PE ratio of 12.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.